X
<

GlaxoSmithKline’s Latest Developments and Valuation

PART:
1 2 3 4 5 6 7 8 9
Part 3
GlaxoSmithKline’s Latest Developments and Valuation PART 3 OF 9

Quarterly Performance of GlaxoSmithKline’s Segments

GlaxoSmithKline’s segments

GlaxoSmithKline’s (GSK) business is classified and reported in the following three segments:

  • Pharmaceuticals
  • Vaccines
  • Consumer Healthcare

Quarterly Performance of GlaxoSmithKline’s Segments

Interested in GSK? Don't miss the next report.

Receive e-mail alerts for new research on GSK

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

The above chart shows the segment-wise revenues for GlaxoSmithKline over the last few quarters. For 2Q17, the company reported a 2.0% rise in revenues at constant exchange rates to 7.3 billion pounds, driven by increased sales across all three segments.

Segment performances

The Pharmaceuticals segment reported a 12.0% rise in revenues to 4.4 billion pounds in 2Q17 compared to 2Q16, driven by increased sales of new products, including Tivicay, Relvar/Breo Ellipta, and Triumeq. Growth was impacted by recent divestitures. At constant exchange rates, the segment reported a 3.0% rise in 2Q17 revenues compared to 2Q16 revenues.

The Vaccines segment reported a 16.0% rise in revenues to 1.1 billion pounds in 2Q17 compared to 2Q16, driven by an increase in sales of meningitis vaccines and established vaccines in 2Q17. At constant exchange rates, the segment reported a 5.0% rise in 2Q17 revenues compared to 2Q16.

The Consumer Healthcare segment reported a 10.0% rise in revenues to 1.9 billion pounds in 2Q17 compared to 2Q16, driven by increased sales of pain relief products and oral health products. At constant exchange rates, the segment reported nearly flat revenues in 2Q17 compared to 2Q16 revenues.

We’ll look at the performances of each segment later in this series.

The BLDRS Developed Markets 100 ADR ETF (ADRD) has 2.4% of its total assets in GlaxoSmithKline. ADRD also has 2.1% in Novo Nordisk (NVO), 2.7% in Sanofi (SNY), and 5.5% in Novartis (NVS).

X

Please select a profession that best describes you: